Powered by Google Google ÜbersetzerGoogle Übersetzer
Originaltext
Diese Übersetzung bewerten
Mit deinem Feedback können wir Google Übersetzer weiter verbessern
Latest Press Releases
View all
TimeHeadline
17m agoALIGHT CLASS ACTION DEADLINE FRIDAY: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Alight, Inc. and Urges Investors to Contact the Firm Before May 15th
17m agoFaraday Future Announces First Quarter 2026 Earnings Release Date and Conference Call to be Held on May 14, 2026
17m agoSportradar Investor News: If You Have Suffered Losses in Sportradar Group AG (NASDAQ: SRAD), You Are Encouraged to Contact The Rosen Law Firm About Your Rights
17m agoECN Capital Reports US$0.04 in Adjusted Net Income per Common Share in Q1 2026
18m agoVerde Clean Fuels, Inc. Reports Q1 2026 Results
Denali Therapeutics Inc. logo

Denali Therapeutics Inc.

About

Denali Therapeutics Inc. — investor relations, events, news, and company updates on 6ix.

Latest News

May 7 2026
Denali Therapeutics Reports First Quarter 2026 Financial Results and Business Highlights
Apr 20 2026
Orsini Selected as the Exclusive Specialty Pharmacy and Home Infusion Partner for Denali Therapeutics' AVLAYAH™ (tividenofusp alfa-eknm)
Apr 3 2026
Denali Therapeutics Regains Full Rights to Investigational Therapy DNL593 (PTV:PGRN) for GRN-related Frontotemporal Dementia (FTD-GRN)
Mar 25 2026
Denali Therapeutics Announces U.S. FDA Approval of AVLAYAH™ (tividenofusp alfa-eknm) for Treatment of Hunter Syndrome (MPS II)
Feb 26 2026
Denali Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights

Community Chat

Ask AI

6ix6ixAIEvents